Limiting Molecular Testing To People With Thyroid Nodules That Are Bethesda Category III Or IV On Repeat FNA May Reduce Rate Of Surgery Of Histologically Benign Nodules, Research Suggests

Healio (5/10, Monostra) reports, “Limiting molecular testing to people with thyroid nodules that are Bethesda category III or IV on repeat fine-needle aspiration, or FNA, cytology can reduce the rate of surgery of histologically benign nodules,” researche...